Healthcare provider profile · identity verified

Reyhan Demircioglu, MD

Internal Medicine · WAUKESHA, WI · NPI 1215085857

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	533	131
Losartan Potassium	Losartan Potassium	465	120
Rosuvastatin Calcium	Rosuvastatin Calcium	381	110
Omeprazole	Omeprazole	380	105
Amlodipine Besylate	Amlodipine Besylate	379	103
Metoprolol Succinate	Metoprolol Succinate	357	75
Pantoprazole Sodium	Pantoprazole Sodium	341	105
Pravastatin Sodium	Pravastatin Sodium	338	102
Atorvastatin Calcium	Atorvastatin Calcium	312	94
Spironolactone	Spironolactone	289	78
Lisinopril	Lisinopril	277	78
Gabapentin	Gabapentin	239	80
Montelukast Sodium	Montelukast Sodium	229	60
Hydrochlorothiazide	Hydrochlorothiazide	149	54
Metformin Hcl Er	Metformin Hcl	135	39
Sertraline Hcl	Sertraline Hcl	131	37
Trazodone Hcl	Trazodone Hcl	123	33
Duloxetine Hcl	Duloxetine Hcl	120	28
Atenolol	Atenolol	114	38
Furosemide	Furosemide	111	28
Simvastatin	Simvastatin	106	32
Citalopram Hbr	Citalopram Hydrobromide	105	28
Mounjaro	Tirzepatide	104	24
Fluticasone Propionate	Fluticasone Propionate	102	43
Alendronate Sodium	Alendronate Sodium	95	21
Allopurinol	Allopurinol	94	26
Celecoxib	Celecoxib	92	34
Tramadol Hcl	Tramadol Hcl	91	28
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	90	26
Carvedilol	Carvedilol	86	23
Mirtazapine	Mirtazapine	81	19
Potassium Chloride	Potassium Chloride	77	32
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	73	13
Escitalopram Oxalate	Escitalopram Oxalate	73	21
Lovastatin	Lovastatin	71	21
Metformin Hcl	Metformin Hcl	70	24
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	68	15
Eliquis	Apixaban	67	16
Memantine Hcl	Memantine Hcl	65	16
Clopidogrel	Clopidogrel Bisulfate	64	22
Albuterol Sulfate Hfa	Albuterol Sulfate	61	36
Rybelsus	Semaglutide	61	16
Jardiance	Empagliflozin	60	16
Fluoxetine Hcl	Fluoxetine Hcl	59	16
Tamsulosin Hcl	Tamsulosin Hcl	57	19
Clonazepam	Clonazepam	51	13
Warfarin Sodium	Warfarin Sodium	50	16
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	48	suppressed
Buspirone Hcl	Buspirone Hcl	47	suppressed
Ozempic	Semaglutide	47	suppressed
Synthroid	Levothyroxine Sodium	46	15
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	46	14
Estradiol	Estradiol	44	25
Ketoconazole	Ketoconazole	43	37
Pregabalin	Pregabalin	43	12
Rabeprazole Sodium	Rabeprazole Sodium	40	suppressed
Valsartan	Valsartan	40	11
Triamcinolone Acetonide	Triamcinolone Acetonide	37	27
Ipratropium Bromide	Ipratropium Bromide	33	15
Breo Ellipta	Fluticasone/Vilanterol	32	suppressed
Myrbetriq	Mirabegron	31	suppressed
Bupropion Xl	Bupropion Hcl	29	suppressed
Famotidine	Famotidine	28	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	28	suppressed
Donepezil Hcl	Donepezil Hcl	27	suppressed
Irbesartan	Irbesartan	26	suppressed
Diclofenac Sodium	Diclofenac Sodium	24	suppressed
Ramipril	Ramipril	24	suppressed
Tizanidine Hcl	Tizanidine Hcl	24	14
Lorazepam	Lorazepam	23	12
Oxybutynin Chloride	Oxybutynin Chloride	23	suppressed
Paroxetine Hcl	Paroxetine Hcl	23	suppressed
Spiriva Handihaler	Tiotropium Bromide	23	suppressed
Nystatin	Nystatin	22	15
Alprazolam	Alprazolam	20	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	20	18
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Mupirocin	Mupirocin	20	suppressed
Vascepa	Icosapent Ethyl	20	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	20	suppressed
Bupropion Hcl Sr	Bupropion Hcl	19	suppressed
Cephalexin	Cephalexin	19	14
Ezetimibe	Ezetimibe	19	suppressed
Methocarbamol	Methocarbamol	19	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	19	suppressed
Finasteride	Finasteride	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Ondansetron Odt	Ondansetron	18	12
Glipizide	Glipizide	17	suppressed
Meloxicam	Meloxicam	17	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	17	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Prednisone	Prednisone	15	11
Qvar Redihaler	Beclomethasone Dipropionate	15	suppressed
Telmisartan	Telmisartan	15	suppressed
Verapamil Er	Verapamil Hcl	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Fluconazole	Fluconazole	14	13
Januvia	Sitagliptin Phosphate	14	suppressed
Arnuity Ellipta	Fluticasone Furoate	13	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	13	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	13	suppressed
Divalproex Sodium	Divalproex Sodium	13	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	13	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Acebutolol Hcl	Acebutolol Hcl	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error